SPRO logo

Spero Therapeutics (SPRO) Cash From Operations

Annual CFO

-$32.99 M
-$25.26 M-326.79%

December 31, 2023

Summary

Performance

1-Year Change

-326.79%

3-Year Change

+61.58%

5-Year Change

+16.73%

15-Year Change

+15.64%

SPRO Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

36.98%
SPRO annual cash flow from operations is higher than 36.98% of companies in Healthcare sector

High & Low

All-time High

-$7.73 M

3-Year Low

-$64.35 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
SPRO previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Mar 13, 2025
SPRO next annual earnings announcement is scheduled for Mar 13, 2025

OtherSPROcash flowmetrics:

Annual CFI

$0.00
SPRO annual cash flow from investing activities is $0.00

Annual CFF

$221.00 K
SPRO annual cash flow from financing activities is $221.00 thousand

Annual FCF

-$32.99 M
SPRO annual free cash flow is -$32.99 million

Annual CAPEX

-
SPRO annual capital expenditures value is unknown

Quarterly CFO

$12.76 M
+$31.51 M+168.09%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+172.96%

3-Year Change

+172.96%

5-Year Change

+172.96%

SPRO Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

83.07%
SPRO quarterly cash flow from operations is higher than 83.07% of companies in Healthcare sector

High & Low

All-time High

$44.48 M
SPRO quarterly cash flow from operations is currently -71.31% below its historical high of $44.48 million

3-Year Low

-$28.22 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
SPRO previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 13, 2025
SPRO next earnings announcement is scheduled for Mar 13, 2025

OtherSPROcash flowmetrics:

Quarterly CFI

-
SPRO quarterly cash flow from investing activities value is unknown

Quarterly CFF

$0.00
SPRO quarterly cash flow from financing activities is $0.00

Quarterly FCF

$12.76 M
SPRO quarterly free cash flow is $12.76 million

Quarterly CAPEX

-
SPRO quarterly capital expenditures value is unknown

TTM CFO

-$17.54 M
-$3.15 M-21.91%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+46.85%

3-Year Change

+46.85%

5-Year Change

+46.85%

SPRO TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

48.35%
SPRO TTM cash flow from operations is higher than 48.35% of companies in Healthcare sector

High & Low

All-time High

$28.98 M
SPRO TTM cash flow from operations is currently -160.51% below its historical high of $28.98 million

3-Year Low

-$83.56 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
SPRO previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 13, 2025
SPRO next earnings announcement is scheduled for Mar 13, 2025

OtherSPROcash flowmetrics:

TTM CFI

-
SPRO TTM cash flow from investing activities value is unknown

TTM CFF

$1000.00
SPRO TTM cash flow from financing activities is $1000.00

TTM FCF

-$17.54 M
SPRO TTM free cash flow is -$17.54 million

TTM CAPEX

-
SPRO TTM capital expenditures value is unknown

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

SPRO Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-326.8%+173.0%+46.9%
3 y3 years+61.6%+173.0%+46.9%
5 y5 years+16.7%+173.0%+46.9%

SPRO Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-326.8%+48.7%-71.3%+145.2%-160.5%+79.0%
5 y5-year-326.8%+61.6%-71.3%+145.2%-160.5%+79.8%
alltimeall time-326.8%+61.6%-71.3%+145.2%-160.5%+79.8%

Spero Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2024
-
$12.76 M(-168.1%)
-$17.54 M(+21.9%)
Jun 2024
-
-$18.74 M(-415.7%)
-$14.38 M(+1.3%)
Mar 2024
-
$5.94 M(-133.9%)
-$14.20 M(-57.0%)
Dec 2023
-$32.99 M(+326.8%)
-$17.49 M(-209.9%)
-$32.99 M(-213.9%)
Sep 2023
-
$15.91 M(-185.7%)
$28.98 M(+139.3%)
Jun 2023
-
-$18.56 M(+44.4%)
$12.11 M(+58.5%)
Mar 2023
-
-$12.85 M(-128.9%)
$7.64 M(-198.8%)
Dec 2022
-$7.73 M(-88.0%)
$44.48 M(-4748.1%)
-$7.73 M(-90.3%)
Sep 2022
-
-$957.00 K(-95.8%)
-$79.56 M(-4.8%)
Jun 2022
-
-$23.03 M(-18.4%)
-$83.56 M(+8.4%)
Mar 2022
-
-$28.22 M(+3.2%)
-$77.09 M(+19.8%)
Dec 2021
-$64.35 M(-25.1%)
-$27.35 M(+452.3%)
-$64.35 M(+20.5%)
Sep 2021
-
-$4.95 M(-70.1%)
-$53.38 M(-23.4%)
Jun 2021
-
-$16.57 M(+7.0%)
-$69.69 M(-10.7%)
Mar 2021
-
-$15.48 M(-5.5%)
-$78.02 M(-9.1%)
Dec 2020
-$85.87 M
-$16.38 M(-23.0%)
-$85.87 M(-1.1%)
DateAnnualQuarterlyTTM
Sep 2020
-
-$21.26 M(-14.6%)
-$86.86 M(+15.4%)
Jun 2020
-
-$24.90 M(+6.7%)
-$75.25 M(+20.5%)
Mar 2020
-
-$23.33 M(+34.3%)
-$62.42 M(+24.8%)
Dec 2019
-$50.02 M(+26.2%)
-$17.37 M(+79.8%)
-$50.02 M(+8.4%)
Sep 2019
-
-$9.66 M(-20.0%)
-$46.16 M(+9.9%)
Jun 2019
-
-$12.07 M(+10.5%)
-$42.02 M(+8.9%)
Mar 2019
-
-$10.92 M(-19.1%)
-$38.59 M(-2.6%)
Dec 2018
-$39.63 M(+1.3%)
-$13.51 M(+145.0%)
-$39.63 M(+2.0%)
Sep 2018
-
-$5.51 M(-36.2%)
-$38.86 M(-11.4%)
Jun 2018
-
-$8.64 M(-27.8%)
-$43.86 M(-0.5%)
Mar 2018
-
-$11.96 M(-6.1%)
-$44.09 M(+12.7%)
Dec 2017
-$39.11 M(+35.1%)
-$12.74 M(+21.2%)
-$39.11 M(+48.3%)
Sep 2017
-
-$10.52 M(+18.5%)
-$26.37 M(+66.3%)
Jun 2017
-
-$8.88 M(+27.2%)
-$15.86 M(+127.2%)
Mar 2017
-
-$6.98 M
-$6.98 M
Dec 2016
-$28.96 M(+201.4%)
-
-
Dec 2015
-$9.61 M
-
-

FAQ

  • What is Spero Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Spero Therapeutics?
  • What is Spero Therapeutics annual CFO year-on-year change?
  • What is Spero Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Spero Therapeutics?
  • What is Spero Therapeutics quarterly CFO year-on-year change?
  • What is Spero Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Spero Therapeutics?
  • What is Spero Therapeutics TTM CFO year-on-year change?

What is Spero Therapeutics annual cash flow from operations?

The current annual CFO of SPRO is -$32.99 M

What is the all time high annual CFO for Spero Therapeutics?

Spero Therapeutics all-time high annual cash flow from operations is -$7.73 M

What is Spero Therapeutics annual CFO year-on-year change?

Over the past year, SPRO annual cash flow from operations has changed by -$25.26 M (-326.79%)

What is Spero Therapeutics quarterly cash flow from operations?

The current quarterly CFO of SPRO is $12.76 M

What is the all time high quarterly CFO for Spero Therapeutics?

Spero Therapeutics all-time high quarterly cash flow from operations is $44.48 M

What is Spero Therapeutics quarterly CFO year-on-year change?

Over the past year, SPRO quarterly cash flow from operations has changed by +$30.26 M (+172.96%)

What is Spero Therapeutics TTM cash flow from operations?

The current TTM CFO of SPRO is -$17.54 M

What is the all time high TTM CFO for Spero Therapeutics?

Spero Therapeutics all-time high TTM cash flow from operations is $28.98 M

What is Spero Therapeutics TTM CFO year-on-year change?

Over the past year, SPRO TTM cash flow from operations has changed by +$15.46 M (+46.85%)